Article
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
The pharmacogenomics journal - 1 Dec 2017
Hertz D L, Kidwell K M, Seewald N J, Gersch C L, Desta Z, Flockhart D A, Storniolo A-M, Stearns V, Skaar T C, Hayes D F, Henry N L, Rae J M
Abstract excerpt
Discovery of clinical and genetic predictors of exemestane pharmacokinetics was attempted in 246 postmenopausal patients with breast cancer enrolled on a prospective clinical study. A sample was collected 2 h after exemestane dosing at a 1- or 3-month study visit to measure drug concentration. The primary hypothesis was that patients carrying the low-activity CYP3A4*22 (rs35599367) single-nucleotide polymorphism...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.